nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.01.2016 | Original Article – Cancer Research

Riproximin modulates multiple signaling cascades leading to cytostatic and apoptotic effects in human breast cancer cells

verfasst von: Asim Pervaiz, Michael Zepp, Hassan Adwan, Martin R. Berger

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Riproximin, a type II ribosome-inactivating protein (RIP), has shown significant cytotoxic effects in diverse types of cancer cells. To better understand its therapeutic potential, elaborated investigations on the mechanistic aspects of riproximin deem crucial. In this study, we focused on riproximin-mediated changes in cellular properties and corresponding molecular pathways in breast cancer cells.

Methods

Cytotoxicity of riproximin was determined by MTT assay, while the clonogenic and migratory effects were determined by colony formation, migration, and scratch assays. Cytostatic and apoptotic effects were studied by flow cytometry and nuclear staining procedures. Alterations at molecular levels were scrutinized by means of microarray and qRT-PCR methodologies.

Results

Riproximin induced significant cytotoxic effects in the selected human breast cancer cells MDA-MB-231 and MCF-7. Profound inhibition of migration and colony formation were observed in both cell lines in response to riproximin exposure. Concomitantly, a significant arrest in S phase and nuclear fragmentation were observed as causes for its cytostatic and apoptotic effects, respectively. Genetic profiling revealed pronounced induction of the anticancer cytokine IL24/MDA-7 and ER-stress-related GADD genes. In addition, prominent inhibition of the genes relevant to migration (RHO GTPases), anti-apoptotic activities (BCL family), and cell cycle (cyclins) was also noticed.

Conclusion

Riproximin, with its significant antineoplastic effects, modulates multiple cytostatic and apoptotic pathways in breast cancer cells. Results from these investigations highlight the future therapeutic potential of this naturally occurring compound for breast cancer.

Adwan H, Bayer H, Pervaiz A, Sagini M, Berger MR (2014a) Riproximin is a recently discovered type II ribosome inactivating protein with potential for treating cancer. Biotechnol Adv 32(6):1077–1090. doi:10.1016/j.biotechadv.2014.03.008 PubMedCrossRef

Adwan H, Murtaja A, Kadhim Al-Taee K, Pervaiz A, Hielscher T, Berger MR (2014b) Riproximin’s activity depends on gene expression and sensitizes PDAC cells to TRAIL. Cancer Biol Ther 15(9):1185–1197. doi:10.4161/cbt.29503 PubMedPubMedCentralCrossRef

Ahn SG et al (2013) Prognostic factors for patients with bone-only metastasis in breast cancer. Yonsei Med J 54(5):1168–1177. doi:10.3349/ymj.2013.54.5.1168 PubMedPubMedCentralCrossRef

Bagga S, Seth D, Batra JK (2003) The cytotoxic activity of ribosome-inactivating protein saporin-6 is attributed to its rRNA N-glycosidase and internucleosomal DNA fragmentation activities. J Biol Chem 278(7):4813–4820. doi:10.1074/jbc.M207389200 PubMedCrossRef

Bayer H et al (2012a) Evaluation of riproximin binding properties reveals a novel mechanism for cellular targeting. J Biol Chem 287(43):35873–35886. doi:10.1074/jbc.M112.368548 PubMedPubMedCentralCrossRef

Bayer H, Ey N, Wattenberg A, Voss C, Berger MR (2012b) Purification and characterization of riproximin from Ximenia americana fruit kernels. Protein Expr Purif 82(1):97–105. doi:10.1016/j.pep.2011.11.018 PubMedCrossRef

Bhutia SK et al (2013) Targeting breast cancer-initiating/stem cells with melanoma differentiation-associated gene-7/interleukin-24. Int J Cancer 133(11):2726–2736. doi:10.1002/ijc.28289 PubMedPubMedCentral

Brooks SC, Locke ER, Soule HD (1973) Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248(17):6251–6253PubMed

Cailleau R, Young R, Olive M, Reeves WJ Jr (1974) Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53(3):661–674PubMed

Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20):6243s–6249s. doi:10.1158/1078-0432.Ccr-06-0931 PubMedCrossRef

Cretu A, Sha X, Tront J, Hoffman B, Liebermann DA (2009) Stress sensor Gadd45 genes as therapeutic targets in cancer. Cancer Ther 7(A):268–276PubMedPubMedCentral

Daniels-Wells TR et al (2013) Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. Toxicol In Vitro 27(1):220–231. doi:10.1016/j.tiv.2012.10.006 PubMedPubMedCentralCrossRef

Dash R et al (2014) Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction. Cancer Res 74(2):563–574. doi:10.1158/0008-5472.Can-13-1062 PubMedPubMedCentralCrossRef

de Virgilio M, Lombardi A, Caliandro R, Fabbrini MS (2010) Ribosome-inactivating proteins: from plant defense to tumor attack. Toxins 2(11):2699–2737. doi:10.3390/toxins2112699 PubMedPubMedCentralCrossRef

Fan X, He L, Meng Y, Li G, Li L, Meng Y (2015) Alpha-MMC and MAP30, two ribosome-inactivating proteins extracted from Momordica charantia, induce cell cycle arrest and apoptosis in A549 human lung carcinoma cells. Mol Med Rep 11(5):3553–3558. doi:10.3892/mmr.2015.3176 PubMed

Fang EF et al (2012a) Trichosanthin inhibits breast cancer cell proliferation in both cell lines and nude mice by promotion of apoptosis. PLoS One 7(9):e41592. doi:10.1371/journal.pone.0041592 PubMedPubMedCentralCrossRef

Fang EF et al (2012b) Momordica charantia lectin, a type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro and in vivo. Cancer Prev Res 5(1):109–121. doi:10.1158/1940-6207.Capr-11-0203 CrossRef

Feyssa DH, Njoka JT, Asfaw Z, Nyangito MM (2012) Uses and management of Ximenia americana, olacaceae in semi-arid east Shewa, Ethiopia. Pak J Bot 44(4):1177–1184

Fong WP, Mock WY, Ng TB (2000) Intrinsic ribonuclease activities in ribonuclease and ribosome-inactivating proteins from the seeds of bitter gourd. Int J Biochem Cell Biol 32(5):571–577PubMedCrossRef

Gasperi-Campani A, Zoli W, Volpi A, Roncuzzi L, Amadori D (1991) Inhibition of growth of breast cancer cells in vitro by the ribosome-inactivating protein saporin 6. Anticancer Res 11(2):1007–1011PubMed

Hartley MR, Lord JM (2004) Cytotoxic ribosome-inactivating lectins from plants. Biochim Biophys Acta 1701(1–2):1–14. doi:10.1016/j.bbapap.2004.06.004 PubMedCrossRef

Horrix C, Raviv Z, Flescher E, Voss C, Berger MR (2011) Plant ribosome-inactivating proteins type II induce the unfolded protein response in human cancer cells. Cell Mol Life Sci 68(7):1269–1281. doi:10.1007/s00018-010-0524-2 PubMedCrossRef

Huang J et al (2009) [The effect of Rac1 siRNA on the biological behaviors of gastrointestinal cancer cells]. Sichuan da xue xue bao Yi xue ban = Journal of Sichuan University Medical science edition 40(4):588–592

Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O’Brien SM (2001) Homoharringtonine: history, current research, and future direction. Cancer 92(6):1591–1605PubMedCrossRef

Kienle GS, Glockmann A, Schink M, Kiene H (2009) Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res CR 28:79. doi:10.1186/1756-9966-28-79

Lebedeva IV et al (2007) mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol 31(5):985–1007PubMed

Li CJ, Tsang SF, Tsai CH, Tsai HY, Chyuan JH, Hsu HY (2012) Momordica charantia extract induces apoptosis in human cancer cells through caspase- and mitochondria-dependent pathways. Evid Based Complement Alternat Med 2012:261971. doi:10.1155/2012/261971 PubMedPubMedCentral

Li YJ et al (2013) mda-7/IL-24 expression inhibits breast cancer through upregulation of growth arrest-specific Gene 3 (gas3) and disruption of beta 1 Integrin function. Mol Cancer Res 11(6):593–603. doi:10.1158/1541-7786.Mcr-12-0496 PubMedCrossRef

Liao GS, Apaya MK, Shyur LF (2013) Herbal medicine and acupuncture for breast cancer palliative care and adjuvant therapy. Evid Based Complement Alternat Med 2013:437948. doi:10.1155/2013/437948 PubMedPubMedCentral

Lim S, Kaldis P (2013) Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140(15):3079–3093. doi:10.1242/dev.091744 PubMedCrossRef

Lin BW et al (2013) Inhibitory effect of melanoma differentiation associated Gene-7/interleukin-24 on invasion in vitro of human melanoma cancer cells. J Korean Med Sci 28(6):833–839. doi:10.3346/jkms.2013.28.6.833 PubMedPubMedCentralCrossRef

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402–408. doi:10.1006/meth.2001.1262 PubMedCrossRef

Lyu SY, Choi SH, Park WB (2002) Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled pathway independent of p53. Arch Pharmacal Res 25(1):93–101CrossRef

Nan QZ, Gao L, Xiao B, Zhang ZS, Jiang B (2010) [Effect of small interfering RNA targeting Rac1 gene on colony formation of SW480 cells in vitro]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 30(6):1339–1342PubMed

Narayanan S, Surendranath K, Bora N, Surolia A, Karande AA (2005) Ribosome inactivating proteins and apoptosis. FEBS Lett 579(6):1324–1331. doi:10.1016/j.febslet.2005.01.038 PubMedCrossRef

Pan WL, Wong JH, Fang EF, Chan YS, Ye XJ, Ng TB (2013) Differential inhibitory potencies and mechanisms of the type I ribosome inactivating protein marmorin on estrogen receptor (ER)-positive and ER-negative breast cancer cells. Biochim Biophys Acta 1833 5:987–996. doi:10.1016/j.bbamcr.2012.12.013 CrossRef

Parri M, Chiarugi P (2010) Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal. doi:10.1186/1478-811x-8-23 PubMedPubMedCentral

Patani N, Douglas-Jones A, Mansel R, Jiang W, Mokbel K (2010) Tumour suppressor function of MDA-7/IL-24 in human breast cancer. Cancer cell Int 10:29. doi:10.1186/1475-2867-10-29 PubMedPubMedCentral

Peumans WJ, Hao Q, Van Damme EJ (2001) Ribosome-inactivating proteins from plants: more than RNA N-glycosidases? FASEB J 15(9):1493–1506PubMedCrossRef

Puri M, Kaur I, Perugini MA, Gupta RC (2012) Ribosome-inactivating proteins: current status and biomedical applications. Drug Discov Today 17(13–14):774–783. doi:10.1016/j.drudis.2012.03.007 PubMedCrossRef

Ramesh R, Ito I, Gopalan B, Saito Y, Mhashilkar AM, Chada S (2004) Ectopic production of MDA-7/IL-24 inhibits invasion and migration of human lung cancer cells. Mol Ther 9(4):510–518PubMedCrossRef

Roberts LM, Smith DC (2004) Ricin: the endoplasmic reticulum connection. Toxicon 44(5):469–472. doi:10.1016/j.toxicon.2004.07.002 PubMedCrossRef

Saito Y et al (2005) Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation-associated-7 (mda-7)/interleukin-24 (IL-24) gene (vol 12, p 238, 2005). Cancer Gene Ther 12(3):340–340. doi:10.1038/sj.cgt.7700811

Soule HD, Vazguez J, Long A, Albert S, Brennan M (1973) A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51(5):1409–1416PubMed

Stirpe F (2013) Ribosome-inactivating proteins: from toxins to useful proteins. Toxicon 67:12–16. doi:10.1016/j.toxicon.2013.02.005 PubMedCrossRef

Stirpe F, Battelli MG (2006) Ribosome-inactivating proteins: progress and problems. Cell Mol Life Sci 63(16):1850–1866. doi:10.1007/s00018-006-6078-7 PubMedCrossRef

Su ZZ et al (2003) Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 22(8):1164–1180. doi:10.1038/sj.onc.1206062 PubMedCrossRef

Tang W, Hemm I, Bertram B (2003a) Recent development of antitumor agents from Chinese herbal medicines. Part II. High molecular compounds(3). Planta Med 69(3):193–201. doi:10.1055/s-2003-38494 PubMedCrossRef

Tang W, Hemm I, Bertram B (2003b) Recent development of antitumor agents from chinese herbal medicines; part I. Low molecular compounds. Planta Med 69(2):97–108. doi:10.1055/s-2003-37718 PubMedCrossRef

Vega FM, Ridley AJ (2008) Rho GTPases in cancer cell biology. FEBS Lett 582(14):2093–2101. doi:10.1016/j.febslet.2008.04.039 PubMedCrossRef

Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36(3):131–149PubMedCrossRef

Voss C, Eyol E, Berger MR (2006a) Identification of potent anticancer activity in Ximenia americana aqueous extracts used by African traditional medicine. Toxicol Appl Pharmacol 211(3):177–187. doi:10.1016/j.taap.2005.05.016 PubMedCrossRef

Voss C, Eyol E, Frank M, von der Lieth CW, Berger MR (2006b) Identification and characterization of riproximin, a new type II ribosome-inactivating protein with antineoplastic activity from Ximenia americana. FASEB J 20(8):1194–1196. doi:10.1096/fj.05-5231fje PubMedCrossRef

Walsh MJ, Dodd JE, Hautbergue GM (2013) Ribosome-inactivating proteins: potent poisons and molecular tools. Virulence 4(8):774–784. doi:10.4161/viru.26399 PubMedPubMedCentralCrossRef

Weigelt B, Peterse JL, van’t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5(8):591–602. doi:10.1038/Nrc1670 PubMedCrossRef

Xiao Z, Hao Y, Liu B, Qian L (2002) Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 43(9):1763–1768. doi:10.1080/1042819021000006295 PubMedCrossRef

Xie JM et al (2011) Antitumor effects of cucurmosin in human chronic myeloid leukemia occur through cell cycle arrest and decrease the Bcl-2/Bax ratio to induce apoptosis. Afr J Pharm Pharmacol 5(7):985–992

Yam CH, Fung TK, Poon RY (2002) Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 59(8):1317–1326PubMedCrossRef

Zerbini LF et al (2006) A novel pathway involving melanoma differentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells. Cancer Res 66(24):11922–11931. doi:10.1158/0008-5472.Can-06-2068 PubMedCrossRef

Titel: Riproximin modulates multiple signaling cascades leading to cytostatic and apoptotic effects in human breast cancer cells
verfasst von: Asim Pervaiz
Michael Zepp
Hassan Adwan
Martin R. Berger
Publikationsdatum: 01.01.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-2013-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Riproximin modulates multiple signaling cascades leading to cytostatic and apoptotic effects in human breast cancer cells

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Morphological and molecular features of oral fluid-derived exosomes: oral cancer patients versus healthy individuals

Fusion with human lung cancer cells elongates the life span of human umbilical endothelial cells and enhances the anti-tumor immunity

Systemic lupus erythematosus and malignancies risk

The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up

Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC

Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie